Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
17h
Hosted on MSNWill Eli Lilly Stock Keep Climbing? Q2 Trial Results Are CrucialEli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results